Top Madison, WI Biotech Companies (27)
Cellara is an early-stage Madison, Wisconsin-based biotechnology company developing workflow solutions to address critical issues.
At NorthStar Medical Radioisotopes, our mission is to provide patients global access to game-changing radiopharmaceuticals. We are a growing, commercial-stage company focused on advancing patient care by providing therapeutic radioisotopes and novel radiopharmaceuticals to detect and treat cancer, and customized radiopharmaceutical development services. Radiopharmaceutical therapy is increasingly important for cancer treatment, and NorthStar is expanding our industry-leading position in developing commercial-scale production technologies to meet this important healthcare need. We routinely produce the therapeutic radioisotope copper-67 (Cu-67) and are poised to be one of the first commercial-scale producers of non-carrier-added (n.c.a.) actinium-225 (Ac-225), using first-in-kind and environmentally preferable electron accelerator technology. NorthStar’s Radiopharmaceutical Contract Development and Manufacturing Organization (CMDO/CMO) unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. At NorthStar, we prioritize professional growth of our employees. Working with our cutting-edge technology offers a stimulating and rewarding environment for talented individuals who want to be part of our exciting and growing business. We are committed to providing our employees with fulfilling work experiences and valuable career development opportunities.
OUR MISSION: Empower Discovery. Enable Innovation. Improve Life. For over 25 years, Mirus Bio has pioneered the development of transfection reagents and proprietary technologies for nucleic acid delivery applications. Our work is both technical and cutting-edge, and we promote a culture of creativity, responsibility, and respect. Our team members are engaged and motivated by the desire to support our customers and partners to achieve strong results. Mirus, together with Gamma Biosciences, is establishing the future of science and medicine by developing products that enable product developers within the cell and gene therapy space. As we approach a new era of addressing and conquering life-altering diseases, we will continue to expand our expertise and leadership in transfection to be integral in the future of advanced therapies. Mirus Bio is a Gamma Biosciences Company.
At Accuray, we make a direct and powerful impact on the lives of cancer patients every day — helping them live longer, better lives. But our commitment to innovation offers a truly unique opportunity: the chance to change the fight against cancer — helping to develop, introduce and support new treatment delivery systems and software that will give new hope and new health to cancer patients and cancer survivors around the world. Accuray develops, manufactures and sells radiotherapy systems for alternative cancer treatments. Our radiation therapy for cancer makes treatment shorter, safer, personalized and more effective, ultimately enabling patients to live longer, better lives.
Atterx develops therapeutics to fight the growing epidemic of antibiotic resistant bacteria.
Genome International Corporation (GIC) is a research-driven firm.
Fujifilm Cellular Dynamics, Inc. develops and manufactures biologically relevant human cells derived from induced pluripotent stem (iPS) cells. Our iCell® and donor-specific MyCell® Products are highly pure, highly reproducible, and available in industrial quantity to enable drug discovery, toxicity testing, stem cell banking, and cell therapy development.
At Promega Corporation, creativity and connection drive discovery and innovation. We celebrate scientific discovery and the creative application of science to solve problems. Interactions with our customers, partners and vendors are central to everything we do, and we value those relationships. We seek out and build connections across the globe and in our local communities because creative problem solving requires a network of diverse ideas and viewpoints.
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Elephas is developing a technology platform to assess how live tumor cells respond to cancer therapies. We are harnessing the latest advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence to revolutionize cancer treatment. Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite advances in precision medicine and a significant increase in the number of available therapies, many cancer patients still derive no benefit from their treatment. Immunotherapy is an emerging type of treatment that can greatly benefit patients when it is successful. Unfortunately, today only 1 in 3 patients receiving therapy respond and only 1 in 5 receiving immunotherapy respond. We maintain the native 3-dimensional cellular architecture of a patient’s tumor and enable ex-vivo real-time profiling of live tumor samples. The platform is being developed for use with immunotherapy agents alone and in combination with traditional chemotherapy and targeted therapies. THE ELEPHAS MISSION To develop innovative cancer diagnostic products and services that enable accurate prediction of clinical treatment outcomes and accelerate drug development
Platypus Technologies develops analytical and life sciences products based upon the application of nanotechnology and materials science.
Nimble Therapeutics is bringing the power of massively parallel chemical synthesis to drug discovery.
Intuitive Biosciences provides tuberculosis and specific pathogen-free tests for non-human primate (NHP) research operations.
Stem Pharm's synthetic biomaterials support the optimization of cell expansion
BioSentinel develops innovative tools and reagents for the study of botulinum neurotoxin (BoNT).
Proteovista is a microarray technology and applications for basic research and drug discovery company
Invenra is focused on developing the next generation of best-in-class biologics, with an emphasis on multispecific antibodies and their derivatives. Invenra's proprietary technologies combine our highly developable B-Body™ bispecific platform with high throughput functional screening, enabling the optimization of unprecedented numbers of bispecific antibodies in phenotypic assays. Invenra has a pipeline of immuno-oncology bispecific antibodies that are currently in preclinical studies.
FluGen is a biopharmaceutical company specializing on the prevention and treatment of seasonal and pandemic influenza worldwide.
Cellscript is a pharmaceutical company
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Work Your Passion. Live Your Purpose.
Industry
Work Your Passion. Live Your Purpose.
